Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Mind Medicine (MindMed) Inc N.MMED.WA


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

NDAQ:MNMD - Post Discussion

Mind Medicine (MindMed) Inc > Valuation::: Easy $10 ๐Ÿ‘‰๐“‹ผ๐Ÿค‘๐“‹ผ๐Ÿ‘ˆ Canopy of Mushroom Space!!
View:
Post by GajjarDr on Apr 29, 2021 12:50pm

Valuation::: Easy $10 ๐Ÿ‘‰๐“‹ผ๐Ÿค‘๐“‹ผ๐Ÿ‘ˆ Canopy of Mushroom Space!!

Next-Gen Psychedelic Innovation

MindMed is discovering and researching a broad range of novel compounds, therapies, and technologies with the goal of unlocking new pathways for patients. 

Technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient are imperative to the patient experience. This technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. The R&D is taking place in collaboration with the University Hospital Basel’s Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.
Comment by markovschrilovo on Apr 29, 2021 1:02pm
Comment by markovschrilovo on Apr 29, 2021 1:06pm
What I am most interested in is the fact that BIG BANKS // intitutions have bought in && how the patents will sell to a broad market. https://www.fxstreet.com/news/mnmd-stock-price-mind-medicine-rebounds-after-a-rocky-nasdaq-debut-202104291115
Comment by noeIstrlfe on Apr 29, 2021 11:56pm
$50
Comment by Unimaginatively on Apr 29, 2021 1:58pm
like canopy growth corp? Aye possible. The mushroom giant of the business. I'm in chart looks paved for a massive next level up. Cup and Handle formation ^^^^ I'll take some money off table on next 52 week high. Good luck to all
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities